Tested Applications
| Positive IHC detected in | human tonsillitis tissue, human lymphoma tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | human tonsillitis tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:500-1:2000 |
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
18106-1-AP targets PD-1/CD279 in IHC, IF-P, IP, CoIP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag12470 Product name: Recombinant human PD-1/CD279 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-288 aa of BC074740 Sequence: MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL Predict reactive species |
| Full Name | programmed cell death 1 |
| Calculated Molecular Weight | 288 aa, 32 kDa |
| GenBank Accession Number | BC074740 |
| Gene Symbol | PD-1 |
| Gene ID (NCBI) | 5133 |
| RRID | AB_10732952 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q15116 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436). It has been reported that PD-1 is heavily glycosylated and migrates with an apparent molecular mass of 47-55 kDa on SDS-PAGE , which is larger than its predicted mass of 32 kDa (PMID: 8671665; 17640856; 17003438).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for PD-1/CD279 antibody 18106-1-AP | Download protocol |
| IHC protocol for PD-1/CD279 antibody 18106-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
PD-1 antibody (Cat# 18106-1-AP) has accumulated 116 citations across high-impact journals including Cancer Cell, Nature Metabolism, Nature Communications, Theranostics, Advanced Science, Molecular Therapy, Cancer Letters, Journal for ImmunoTherapy of Cancer, and Frontiers in Immunology. Key research fields include cancer immunotherapy and immune checkpoint biology, tumor microenvironment characterization, multiple malignancies such as hepatocellular carcinoma, glioblastoma, breast cancer, gastric cancer, and lung cancer, nanomedicine-based immunotherapy strategies, autoimmune and inflammatory diseases, and infectious disease immunology.
| Species | Application | Title |
|---|---|---|
Cancer Cell Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis | ||
Cancer Cell Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer | ||
Nat Metab The antitumour effects of caloric restriction are mediated by the gut microbiome | ||
Nat Commun ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy | ||
J Adv Res Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling | ||
J Nanobiotechnology Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells |
